Hexarelin stimulates pulsatile GH secretion, reducing visceral fat and improving insulin sensitivity in obese mice.
Background
Individuals with obesity often exhibit low growth hormone (GH) secretion, creating a vicious cycle of reduced lipid mobilization and further fat accumulation. While therapeutic approaches like direct GH injection or using GH-releasing hormone (GHRH) receptor agonists can reduce fat, they are often plagued by negative side effects on glucose metabolism and the high cost of manufacturing large peptide molecules, which has hindered their widespread clinical use. This study explores an alternative strategy: activating the growth hormone secretagogue receptor (GHSR) to stimulate the body's own endogenous, pulsatile GH secretion, potentially achieving the metabolic benefits of elevated GH without the same adverse effects on glucose control.
Study Design
The study used a hyperphagic obese mouse model: male melanocortin 4 receptor knockout (MC4RKO) mice. The mice were pair-fed to control for food intake differences. The intervention group received a continuous infusion of hexarelin at 10.56 μg/day via an osmotic pump, while the control group received a vehicle infusion. The treatment period lasted for 3-4 weeks. The primary endpoints were changes in GH secretion patterns, fat mass, lipid metabolism in adipose and liver tissue, and markers of glucose homeostasis, including whole-body insulin sensitivity and glucose tolerance.
Results
Hexarelin treatment significantly increased the pulsatile GH secretion without affecting basal GH levels in the obese MC4RKO mice. This physiological change in GH release led to profound metabolic improvements. The treated mice exhibited increased lipolysis and lipid oxidation in adipose tissue and a reduction in de novo lipogenesis in the liver. These effects were accompanied by increased expression of genes involved in GH signaling pathways in both visceral adipose tissue and the liver, suggesting the effects were a direct result of GH action. Importantly, hexarelin treatment improved whole-body insulin sensitivity.
This resulted in a tangible reduction in visceral fat mass and a decrease in liver triglyceride content, all while circulating free fatty acid levels remained unchanged. Crucially, the treatment did not alter glucose tolerance, insulin levels, or insulin-like growth factor 1 (IGF-1) levels, avoiding common side effects seen with other GH-based therapies.
Key Findings
- Continuous hexarelin (10.56 μg/day) significantly increased pulsatile, but not basal, GH secretion in obese MC4RKO mice.
- Hexarelin treatment reduced visceral fat mass and liver triglyceride content.
- The treatment improved whole-body insulin sensitivity in the obese mice.
- Glucose tolerance, insulin levels, and IGF-1 levels were not altered by hexarelin administration.
- Hexarelin increased expression of GH signaling pathway genes in visceral adipose tissue and the liver.
Why It Matters
This study provides evidence that activating the GHSR to enhance the body's natural, pulsatile GH release pattern is a viable strategy for managing obesity and its metabolic complications. For individuals exploring metabolic optimization, this suggests that GHS peptides like hexarelin might offer a way to harness GH's lipolytic benefits while minimizing the risk of insulin resistance often associated with supraphysiological, continuous GH elevation from direct injections. The protocol used—continuous infusion to stimulate pulsatile release—highlights the importance of administration method. While far from a human protocol, this research supports a more nuanced approach to GH-axis modulation, focusing on restoring physiological rhythm rather than simple elevation, potentially offering a safer and more effective therapeutic window for fat loss and improved metabolic health.
